# Novel small-molecule therapies for CF

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $584,722

## Abstract

ABSTRACT
This is a proposal to continue the Cystic Fibrosis (CF) Research and Translation Center at the University of
California, San Francisco and collaborating institutions. The focus of our Center remains the discovery and
advancement of novel small-molecule therapies for CF. The original proposal 15 years ago followed from 5
years of work establishing a unique academic drug discovery program in the laboratories of Dr. Verkman and
collaborators to identify and characterize small-molecule modulators of CFTR. The proposed Center will fund
four scientific Cores and an administrative Core to support the activities of 2 Pilot Projects and at least 22 CF-
related projects. The Core directors are experienced CF investigators with recognized expertise in their areas
of investigation and a history of productive collaboration. The Cores include: High-Throughput Screening (Core
A, Alan Verkman, Director), Assays & Cell Models (Core B, Peter Haggie, Director), Chemistry (Core C, Mark
Kurth (UC Davis) and Marc Anderson (San Francisco State University), co-Directors), and Animal
Pharmacology & Models (Core D, Onur Cil, Director). Major focuses of projects utilizing the Cores include
development of therapies for the `remaining 10%' of CF subjects that are not benefitted by available CFTR
modulators, which include tailored modulators for rare and difficult-to-treat CFTR mutants, and mutation-
agnostic therapies such as SLC26A4 (pendrin) inhibitors and SLC26A9 modulators; and therapies targeting
gastrointestinal and renal complications of CF, such as SLC26A3 (DRA) inhibitors for CF constipation and
enteric hyperoxaluria, and SLC26A6 (PAT-1) inhibitors for CF constipation and meconium ileus. The goal of
the research to be enhanced by the Center remains the development of novel small-molecule therapies for CF
that can be translated into the clinic.

## Key facts

- **NIH application ID:** 10001904
- **Project number:** 2P30DK072517-16
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Peter Michael Haggie
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $584,722
- **Award type:** 2
- **Project period:** 2005-08-01 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10001904

## Citation

> US National Institutes of Health, RePORTER application 10001904, Novel small-molecule therapies for CF (2P30DK072517-16). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10001904. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*